Key Highlights

  • 0.19 USD is the consensus loss per share (an EPS estimate of -0.19) for Immix Biopharma, Inc. (NASDAQ:IMMX) ahead of its November 13, 2026 report, versus a loss of 0.24 per share a year earlier.
  • 232.1 million USD is the cash, equivalents and short-term investments reported at June 30, 2026, with no debt, and management guides to a cash runway of about mid-2028.
  • 12.5 million USD is the operating loss reported for the second quarter of 2026, up 85% year on year, with research spending of 5.33 million USD and administrative spending of 7.12 million USD.
  • 717.94 million USD is the market Capitalization per the screener snapshot, and the report is flagged for after the market closes on November 13, 2026.

What Investors Expect From Immix Biopharma, Inc. (NASDAQ:IMMX) on November 13, 2026

Per the screener snapshot, Immix Biopharma, Inc. reports third quarter 2026 results on November 13, 2026, after the market closes, with a consensus EPS estimate of -0.19 and a market capitalization of USD 717.94 million. In the third quarter of 2025 the company reported a net loss of USD 7.59 million, or USD 0.24 per share, versus USD 7.15 million, or USD 0.24 per share, a year earlier. The nine-month 2025 net loss was USD 18.75 million. Investors will compare the new quarter with a larger spending base and a much larger share count after two Equity raises.

The Rationale: Last Reported Quarter and Management Outlook for Immix Biopharma, Inc. (NASDAQ:IMMX)

For the quarter ended June 30, 2026, an independent analyst note reported an operating loss of USD 12.5 million, up 85% year on year and 15% from the first quarter. Research and Development was USD 5.33 million versus USD 3.97 million a year earlier, and general and administrative expense was USD 7.12 million versus USD 2.75 million. Cash used in operations was USD 11.7 million, versus USD 9.83 million in the first quarter. In the NEXICART-2 trial of NXC-201, 19 of 20 evaluable patients (95%) reached complete response, with 45 patients planned in total. The company has indicated a BLA submission in the first half of 2027 and one-year follow-up data in March 2027.

Valuation, Liquidity and Risks for Immix Biopharma, Inc. (NASDAQ:IMMX)

Liquidity was USD 232.1 million at June 30, 2026, after a May 2026 offering of about 16.8 million shares at USD 8.94 that raised roughly USD 150 million gross and USD 140.7 million net, plus USD 93.7 million net in December 2025. Shares in issue were about 71.5 million. The analyst note cited a Market Value of USD 719 million at USD 10.06 per share, while another figure showed USD 620 million at USD 8.66 as of November 11, 2026, so the market value varies with the share price. Risks include clinical and regulatory outcomes, dilution, cash burn and the fact that the company has no product revenue.

Where Things Stand

Where things stand: Immix Biopharma, Inc. (NASDAQ:IMMX) reports with a consensus EPS estimate of -0.19, a market capitalization of USD 717.94 million per the screener snapshot and USD 232.1 million of cash at June 30, 2026. Operating loss reached USD 12.5 million in the second quarter, reflecting higher research and administrative costs as NXC-201 moves toward a planned BLA submission in the first half of 2027. With no Debt and a runway guided to about mid-2028, attention will fall on spending, trial updates and timelines. The company has no revenue, so results turn on expenses, interest income and share count. This is information only and not Investment advice.